Comparison of initial warfarin response in obese patients versus non-obese patients

Journal of Thrombosis and Thrombolysis

Volumn 36, Issue 1, 2013, Pages 96-101

  Wallace, Jessica L ^a,b,c   Reaves, Anne B ^a,c   Tolley, Elizabeth A ^a   Oliphant, Carrie S ^a,c   Hutchison, Lydia ^a,c   Alabdan, Numan Abdulraman ^a   Sands, Christopher W ^a,c   Self, Timothy H ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b LIPSCOMB UNIVERSITY   (United States)

^c METHODIST UNIVERSITY HOSPITAL   (United States)

Author keywords

Initial dosing; Obesity; Warfarin

Indexed keywords

WARFARIN;

ADULT; ANTICOAGULATION; ARTICLE; BODY MASS; CARDIOGENIC SHOCK; COMORBIDITY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; OBESITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOEMBOLISM; UNDERWEIGHT;

AGED; ANTICOAGULANTS; BODY MASS INDEX; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; OBESITY, MORBID; THINNESS; WARFARIN;

EID: 84879225393     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-012-0811-x     Document Type: Article

References (14)

1. Oake N, Fergusson DA, Forster AJ, van Walraven C (2007) Frequency of adverse events in patients with poor anticoagulation: a meta-analysis. CMAJ 176:1589-1594
2. Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:152S-184S
3. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM (2005) Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127:2049-2056
4. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
5. Schwarz UI, Ritchie D, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008
6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87-94
7. Eichenger S, Hron G, Bialonczyk C et al (2008) Overweight, obesity and the risk of recurrent venous thromboembolism. Arch Intern Med 168(15):1678-1683
8. Zu Schwabedissen CM, Schmitz VMF, Woodruff S et al (2006) Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not. Eur J Clin Pharmacol 62:713-720
9. National Institutes of Health (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Obes Res 6(Suppl 2):51S-209S
10. Eccles JT (1975) Control of warfarin therapy in the elderly. Age Ageing 4:161-165
11. Routledge PA, Chapman PH, Davies DM, Rawlins MD (1979) Factors affecting warfarin requirements. Eur J Clin Pharmacol 15:319-322
12. Kamali F, Khan TI, King BP et al (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204-212
13. Ageno W, Steid L, Ultori C et al (2003) The initial phase of oral anticoagulation with warfarin in outpatients with deep venous thrombosis. Blood Coagul Fibrinolysis 14:11-14
14. Gage BF, Eby C, Johnson JA et al (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84:326-331 Hospital